SCHEDULE: Alphabet Affiliates Disclose 12.3% Stake in Prime Medicine
Beneficial Ownership Report
Alphabet Inc. and its affiliated investment entities have reported a combined beneficial ownership of 12.3% in Prime Medicine, Inc., totaling 16,562,498 shares.
Summary
- Alphabet Inc., through its affiliated investment entities including GV 2019, L.P., GV 2021, L.P., and GV 2023, L.P., collectively beneficially owns 16,562,498 shares of Prime Medicine, Inc. Common Stock.
- This aggregate ownership represents 12.3% of Prime Medicine's outstanding Common Stock.
- The percentage is calculated based on an aggregate total of 134,573,998 shares of Common Stock outstanding as of July 31, 2025, as reported by Prime Medicine in its Quarterly Report for the period ended June 30, 2025.
- GV 2019, L.P. directly owns 10,100,058 shares, accounting for 7.5% of the class.
- GV 2021, L.P. directly owns 3,262,440 shares, accounting for 2.4% of the class.
- GV 2023, L.P. directly owns 3,200,000 shares, accounting for 2.4% of the class.
- Alphabet Holdings LLC, XXVI Holdings Inc., and Alphabet Inc. are deemed to indirectly beneficially own the total 16,562,498 shares.
- The Reporting Persons certify that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of Prime Medicine, Inc.
Sentiment
Score: 6
Explanation: The filing is a routine disclosure of beneficial ownership by Alphabet Inc. affiliated entities. The maintenance of a significant stake (12.3%) by a prominent institutional investor like Alphabet's venture arm could be viewed as a positive signal of confidence in Prime Medicine, Inc., though it is a standard regulatory update.
Positives
- A significant investment from Alphabet Inc. affiliated entities (GV), potentially signaling confidence in Prime Medicine's long-term prospects.
- Increased transparency regarding a major institutional investor's stake in the company.
Risks
- The filing explicitly states that the securities were not acquired for the purpose of changing or influencing control of the issuer, mitigating immediate control-related risks.
Future Outlook
NA
Industry Context
This filing is a standard disclosure of beneficial ownership and does not provide specific industry context beyond identifying Prime Medicine, Inc. as the issuer.
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional investor's stake, which may influence market perception and liquidity.
- Management: Awareness of a major shareholder, though the filing explicitly states no intent to influence control.
Key Dates
| Date | Description |
|---|---|
| 2025-06-30 | End of period for Prime Medicine's Quarterly Report (Form 10-Q) used for outstanding shares calculation. |
| 2025-07-31 | Date as of which 134,573,998 shares of Prime Medicine's Common Stock were outstanding, as reported by the Issuer. |
| 2025-08-07 | Date Prime Medicine filed its Quarterly Report on Form 10-Q with the SEC. |
| 2025-09-30 | Date of event which required the filing of this Schedule 13G (Amendment No. 3). |
| 2025-11-12 | Signature date of the Schedule 13G filing. |
Keywords
Prime Medicine Inc., Alphabet Inc., GV, beneficial ownership, Schedule 13G, common stock, equity stake, institutional investment
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.